Clinical Trials Logo

Lymphoma, B-cell clinical trials

View clinical trials related to Lymphoma, B-cell.

Filter by:
  • Enrolling by invitation  
  • Page 1 ·  Next »

NCT ID: NCT05797948 Enrolling by invitation - Clinical trials for Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

GZL Sequential CD19/CD22 CAR-T in Relapsed or Refractory B-cell Non-Hodgkin Lymphoma

Start date: July 1, 2022
Phase: N/A
Study type: Interventional

This study intends to use Obinutuzumab, Zanubrutinib, and Lenalidomide sequential CD19/CD22 CAR-T in the treatment of Relapsed or Refractory B-cell Non-Hodgkin Lymphoma patients. The main purpose of this study is to explore a new treatment mode for R/R B-NHL patients and observe the efficacy and safety of this treatment regimen.

NCT ID: NCT05690191 Enrolling by invitation - Clinical trials for Diffuse Large B-cell Lymphoma

Chidamide in Patients With Recurrent and Refractory Diffuse Large b

Start date: June 1, 2021
Phase:
Study type: Observational

A Multicenter, Prospective, Observational Clinical Protocol for Chidamide in Combination With Rituximab and Lenalidomide (cR2) in Real-world Practice in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

NCT ID: NCT05645744 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

Long-term Follow-up Study in Patients Previously Treated With a Mustang Bio CAR-T Cell Investigational Product.

Start date: September 29, 2021
Phase:
Study type: Observational

A long-term follow-up study to assess safety and efficacy in patients previously treated with Mustang Bio chimeric antigen receptor (CAR)-T cell investigational products.

NCT ID: NCT05332054 Enrolling by invitation - Lymphoma Clinical Trials

Long-Term Follow-up Study

LTFS
Start date: March 16, 2022
Phase:
Study type: Observational

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

NCT ID: NCT05113069 Enrolling by invitation - B Cell Lymphoma Clinical Trials

A Study of SHR-A1912 for Injection in Patients With B Cell Lymphomas

Start date: December 22, 2021
Phase: Phase 1
Study type: Interventional

To assess the safety and tolerability of SHR-A1912 in patients with B cell lymphoma, to determine the dose-limiting toxicity (DLT), maximum tolerated dose (MTD), and recommended phase II dose (RP2D) of SHR-A1912.

NCT ID: NCT04911478 Enrolling by invitation - Clinical trials for Lymphoma, Non-Hodgkin

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

Start date: February 14, 2022
Phase:
Study type: Observational

The purpose of this study is to assess long-term side effects from subjects who receive an Adicet Bio γδ CAR T cell product. Subjects will join this study once they complete the parent interventional study. No additional study drug will be given, but subjects can receive other therapies for their cancer while they are being followed for long term safety in this study. For a period of 15 years from the first administration of Adicet Bio allogeneic γδ CAR T cell product, subjects will be assessed for long-term safety and survival through collection of data that include safety, efficacy, pharmacokinetics and immunogenicity.

NCT ID: NCT04488354 Enrolling by invitation - Clinical trials for Waldenstrom Macroglobulinemia

Long-term Follow-up Study for Patients Treated With CLBR001 CAR-T

Start date: January 21, 2021
Phase: Phase 1
Study type: Interventional

This study is designed as a long-term follow-up study of participants who have receive genetically modified autologous CLBR001 CAR-T cells

NCT ID: NCT04381741 Enrolling by invitation - Clinical trials for Diffuse Large B-cell Lymphoma

CD19 CAR-T Expressing IL7 and CCL19 Combined With PD1 mAb for Relapsed or Refractory Diffuse Large B Cell Lymphoma

CICPD
Start date: June 18, 2020
Phase: Phase 1
Study type: Interventional

Diffuse large B-cell lymphoma (DLBCL) is the most common non-Hodgkin's lymphoma, accounting for 35% of lymphoma. Chimeric antigen receptor T cell (CAR-T) therapy is a new method to treat DLBCL. KTE-C19, published in the New England Medical Journal in December 2017, was used to treat relapsed and refractory B-cell lymphoma. One year of treatment for 111 patients, the total response rate was 82%, and the complete remission rate was 54%. However, a large number of clinical studies have shown that about 20% of patients with B-ALL and 50% of patients with B-NHL cannot achieve complete remission (CR) after CD19-CAR-T treatment. Targeting tumor microenvironment is an important new method to overcome the drug resistance of CAR-T cells. In this study, IL-7 and CCL19 were connected on the basis of traditional second generation CD19 CAR-T cells to construct novel fourth generation CAR-T cells, which can promote the infiltration, accumulation and survival of CAR-T cells in lymphoma tissue, and further enhance the anti-tumor effect of traditional CAR-T cells. At the same time, combined with four generations of CAR-T cells and PD1 monoclonal antibody, PD1 / PDL1 signal pathway was blocked, anti-tumor effect of CAR-T was improved, and immune response and long-term remission rate of DLBCL were improved.

NCT ID: NCT03399747 Enrolling by invitation - Clinical trials for Diffuse Large B-cell Lymphoma

Abbreviated 3 Cycles of Rituximab Plus CHOP(Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients With Completely Excised LocalizedGastrointestinal CD(Cluster of Differentiation Antigen)20(+) Diffuse Large B-cell Lymphoma

Start date: December 7, 2016
Phase: Phase 2
Study type: Interventional

Phase 2 Study of Abbreviated 3 Cycles of Rituximab plus CHOP (Cyclophosphamide, Adriamycin, Vincristine, and Prednisolone) Immunochemotherapy in Patients with Completely Excised Localized Gastrointestinal CD20 (+) Diffuse Large B-cell Lymphoma(SATURDAY STUDY)

NCT ID: NCT03383406 Enrolling by invitation - Clinical trials for Diffuse Large B Cell Lymphoma

A Phase II Trial of Ifosfamide, Etoposide, Cytarabine, and Methotrexate (IVAM) Chemotherapy for Refractory or Relapsed Diffuse Large B Cell Lymphoma

IVAM
Start date: December 1, 2016
Phase: Phase 2
Study type: Interventional

A phase II trial of ifosfamide, etoposide, cytarabine, and methotrexate (IVAM) chemotherapy for refractory or relapsed diffuse large B cell lymphoma